Sastasundar Ventures Limited has informed the Exchange about disclosure under Reg 30 of SEBI (LODR) - Intimation by Sastasundar Healthbuddy Limited, material subsidiary of the Company, regarding Outcome of its Board Meeting for granting in-principle approval to its restructuring process.
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 1.3 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sastasundar Healthbuddy Limited (SHBL), a material subsidiary of Health X Platform Limited, has received in-principle board approval for a restructuring process that may involve a merger and/or demerger, ultimately leading to SHBL merging into its holding company Health X Platform Limited. The goal is to create independent group structures for the company's healthcare and financial services businesses, with shareholders' economic interest expected to remain intact subject to final valuation. The restructuring is contingent on the sale of Mitsubishi Corporation's entire stake in SHBL to Envision India Fund under an SPA dated February 25, 2026. Independent valuers will be appointed, and final implementation is targeted for the next financial year after FY25-26 accounts are finalized.
For shareholders, this is a forward-looking corporate restructuring announcement that could simplify the group structure, but it is still at a very preliminary stage with no definitive ratio, valuation, or scheme details available yet. The stock may see limited immediate reaction until concrete terms are announced; investors should track the SPA completion, valuation report, and subsequent scheme filing.